New drug targets AKT mutations in Hard-to-Treat cancers
NCT ID NCT06400251
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug ipatasertib in 35 adults with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific AKT gene mutation. Ipatasertib is an AKT inhibitor designed to block cancer growth signals. The main goal is to see if the drug can shrink tumors or stop them from growing. Participants will take the drug and undergo biopsies, blood draws, and CT scans to monitor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ipatasertib (an AKT inhibitor drug)
- What this could lead to
- If it works, this could point toward a targeted treatment option for patients with AKT-mutated cancers that are hard to treat.
- What could go wrong
- This is a small, early-phase trial (35 patients) with no control group. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma